ArticleScientific reports2026
Mechanistic role of gut microbiota metabolites in hypertension-insomnia comorbidity via integrated network pharmacology and molecular dynamics.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hypertension and insomnia frequently co-occur, yet their molecular link is unclear. Recent studies indicate that gut microbiota metabolites significantly influence neuroimmune and cardiovascular interactions. This research aimed to explore the role of these gut microbiota derived metabolites in the co-occurrence of hypertension and insomnia through an integrative network pharmacology approach. We extracted 278 gut microbial metabolites and their targets from the gutMGene database. Target prediction was performed using SEA and Swiss Target Prediction. We compiled 13,700 hypertension and 502 insomnia disease-associated targets from six databases, identifying 408 common targets. The 18 core targets were validated through PPI network analysis, KEGG pathway enrichment, and molecular docking. Ligand-target interaction stability was tested with 100 ns molecular dynamics simulations. Drug-likeness and toxicity were assessed using SwissADME and ADMETlab2.0. The PPI network analysis highlighted IL6 and PPARG as key hubs, each with 12 connections. KEGG pathway enrichment pinpointed the IL-17 signaling pathway as crucial, linking it to lipid metabolism and neuroinflammation. Molecular docking showed 3-indolepropionic acid binds strongly to IL6 (Vina score: -5.472 kcal/mol), supported by stable molecular dynamics simulations. Drug-likeness screening identified butyrate and 3-indolepropionic acid as promising, with no hepatotoxicity or cardiotoxicity. The MMTS network analysis emphasized Lacticaseibacillus paracasei as a major regulator of IL-17 signaling pathways. This study highlights the role of the microbiota-metabolite-inflammation axis in hypertension and insomnia comorbidity, suggesting IL-17 inhibition and microbial metabolite supplementation as treatments. It provides a theoretical framework and potential targets for developing gut-derived metabolite-based interventions for hypertension-insomnia comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.